AngioDynamics delivers strong Med Tech-led Q4 growth while FY27 outlook signals slower topline expansion above views
- Q4 2026 non-GAAP EPS -$0.07 (-133% YoY), beating estimates despite ongoing GAAP and adjusted EPS losses.
- Q4 revenue +8% to $86.6M; full-year +9.4% to $320.2M, both pro forma.
- Med Tech revenue +16.7% in Q4 and +18.4% for FY26, now 47% of sales.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.